More or less rituximab? Biology and clinic, regulators and researchers

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))

(2010) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

(2010) P. P. Tak et al.   ANNALS OF THE RHEUMATIC DISEASES

Reduced-dose rituximab in rheumatoid arthritis: Efficacy depends on degree of B cell depletion

(2010) Edward M. Vital et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

(2010) A. Rubbert-Roth et al.   RHEUMATOLOGY

How to dose infliximab in rheumatoid arthritis: new data on a serious issue

(2009) R. F van Vollenhoven   ANNALS OF THE RHEUMATIC DISEASES

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis

(2008) Shouvik Dass et al.   ARTHRITIS AND RHEUMATISM